Resistance-Associated Substitutions (RAS) and Clinical Factors as Determinants of Sofosbuvir-Daclatasvir Treatment Outcomes in Chronic Hepatitis C Patients
Background: Direct acting antivirals (DAAs) have demonstrated remarkable efficacy, in achieving hepatitis C viral (HCV) elimination rates higher than 90%. One particular concern associated with treatment failure is the emergence of resistance associated substitutions (RASs) in the genome. The occurr...
Saved in:
Main Authors: | Juferdy Kurniawan, Anugrah Dwi Handayu, Gita Aprilicia, Darlene Raudhatul Bahri, Irsan Hasan |
---|---|
Format: | Article |
Language: | English |
Published: |
Interna Publishing
2024-10-01
|
Series: | Acta Medica Indonesiana |
Subjects: | |
Online Access: | https://actamedindones.org/index.php/ijim/article/view/2625 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
NS5A replication complex inhibitor daclatasvir in the basis of chronic hepatitis C interferon-free therapy
by: M. V. Mayevskaya, et al.
Published: (2015-12-01) -
Future destinations: how people cured of hepatitis C using direct acting antiviral drugs progress in a new HCV-free world. A thematic analysis
by: Sarah R. Donaldson, et al.
Published: (2025-01-01) -
Five-Year Prospective Follow-Up of Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antiviral Agents
by: Zhang Y, et al.
Published: (2025-01-01) -
Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study
by: T. Berg, et al.
Published: (2019-01-01) -
Genotype 3 is linked to worse liver disease progression in hepatitis C patients even after SVR following DAA therapy
by: Xiping Ran, et al.
Published: (2025-02-01)